Q.4 The first humanized monoclonal antibody approved for the treatment of breast canceris
(A) Rituximab (B) Cetuximab (C) Bevacizumab (D) Herceptin
Herceptin (trastuzumab) marked history as the first humanized monoclonal antibody approved specifically for breast cancer treatment. This breakthrough targeted HER2-positive cases, revolutionizing precision oncology for biotech and medical students.
Correct Answer
(D) Herceptin received FDA approval in 1998 for metastatic HER2-positive breast cancer. Developed by Genentech, this humanized IgG1 antibody binds HER2 extracellular domain, inhibiting signaling and triggering ADCC.
Option Breakdown
(A) Rituximab
Rituximab, approved 1997 for non-Hodgkin lymphoma, targets CD20 on B-cells. Chimeric (not fully humanized) and lacks breast cancer indication.
(B) Cetuximab
Cetuximab, approved 2004 for colorectal cancer, targets EGFR. Chimeric structure; entered market post-Herceptin without breast cancer focus.
(C) Bevacizumab
Bevacizumab (Avastin), approved 2004 for colorectal cancer (later breast), inhibits VEGF angiogenesis. Humanized but not first for breast cancer.
Clinical Milestone
Herceptin established antibody therapy for solid tumors, validating HER2 testing for personalized treatment. Trials showed 15-26% response boost when combined with chemo, extending survival.
